Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 11

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 11
---
 led the oncology business at Wyeth (today part of Pfizer) in the United States and Women’s Health at Novo Nordisk in Denmark. Early in Ms. Hunter’s career, she led sales and marketing at Ciba-Geigy (today part of Novartis) in neuroscience. Ms. Hunter currently serves on the boards of Bavarian Nordic A/S, Vicore Pharma Holdings AB and Sutro Biopharma, Inc. Ms. Hunter earned her B.A. from the University of Michigan and her M. B. A. from the University of Chicago – Booth School of Business.

We believe Ms. Hunter is qualified to serve on our board of directors because of her experience in leadership positions in different roles within the pharmaceutical development and commercialization and across various industries, and her extensive Board directorship experience.

<div align='center'>7</div>

Helen Collins, M.D.– Dr. Collins has served as a member of our Board of Directors since November 2023. Since September 2021, Dr. Collins has served as the Chief Medical Officer of Enliven Therapeutics Inc, a public biopharmaceutical company focused on oncology. Prior to joining Enliven Therapeutics, Dr. Collins served as Chief Medical Officer and Executive Vice President at Five Prime Therapeutics, Inc., a clinical stage biotechnology company focused on oncology that was acquired by Amgen, Inc. Dr. Collins also previously held leadership positions of increasing responsibility at Gilead Sciences, Inc., most recently as Program and Clinical Lead for its BTK and BET inhibitor programs, and at Amgen, Inc., most recently as Global Lead, Oncology Biosimilars. Dr. Collins also practiced as a medical oncologist and hematologist at Redwood Regional Medical Group for twelve years and served as President of the practice for three years. Dr. Collins currently serves on the board of Kura Oncology, Inc., a clinical-stage biotechnology company developing precision medicines for the treatment of cancer. Dr. Collins earned her A.B. in Chemistry from Bryn Mawr College and her M.D. from Johns Hopkins University School of Medicine. She completed her residency in internal medicine at Johns Hopkins Hospital and completed her fellowship in medical oncology at Stanford University. Dr. Collins is board certified in oncology.

We believe Dr. Collins is qualified to serve on our board of directors because of her expertise and specialization in oncology/hematology treatment, oncology drug discovery, and the design and conduct of clinical trials, and her extensive